GSK Bio
NEWS
It’s a busy week for GlaxoSmithKline, although much of it is related to the upcoming demerger of its Consumer Healthcare business. Here’s a look.
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
Master planning for the site is slated to begin in 2022 and will reportedly create one of the largest life sciences cluster in Europe.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.
The board strongly believes that Walmsley is the correct leader for the pharmaceutical business arm of GSK, which is being referred to as New GSK.
JOBS
IN THE PRESS